Basit öğe kaydını göster

dc.contributor.authorZurnacı, Fatma Özlem
dc.contributor.authorGüzel, Mustafa
dc.date.accessioned2022-10-07T10:39:40Z
dc.date.available2022-10-07T10:39:40Z
dc.date.issued2022en_US
dc.identifier.citationZurnacı, F. Ö. ve Güzel, M. (2022). The effects of increased glucose level and glycolysis on SARS CoV-2 infection. Mini-Reviews in Medicinal Chemistry, 22(18). https://doi.org/10.2174/1389557522666220318115350en_US
dc.identifier.issn1389-5575
dc.identifier.issn1875-5607
dc.identifier.urihttps://doi.org/10.2174/1389557522666220318115350
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9812
dc.description.abstractCOVID-19 has entered our lives as an infection with high mortality rates. Although the vaccination process has provided benefits, the death toll remains frightening worldwide. Therefore, drugs and combined therapies that can be used against COVID-19 infection are still being investigat-ed. Most of these antiviral medications are investigational drug candidates that are still in clinical tri-als. In this context, holistic and different approaches for the treatment of COVID-19, including prophylactic use of natural medicines, are under investigation and may offer potential treatment op-tions due to the fact that this is still an unmet medical need of the world. Thus, inhibiting the increased glycolysis in COVID-19 infection with glycolysis inhibitors may be beneficial for patient survival. This short review highlights the potential benefits of glycolysis inhibition as well as controlling the elevated glucose levels in patients with COVID-19.en_US
dc.language.isoengen_US
dc.publisherBentham Science Publishersen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiviral Researchen_US
dc.subjectCOVID-19 Treatmenten_US
dc.subjectDiabetesen_US
dc.subjectGlucose Levelen_US
dc.subjectGlycolysis Inhibitionen_US
dc.subjectSARS-CoV-2en_US
dc.titleThe effects of increased glucose level and glycolysis on SARS CoV-2 infectionen_US
dc.typereviewen_US
dc.relation.ispartofMini-Reviews in Medicinal Chemistryen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsüen_US
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Moleküler Tıp ve Biyoteknoloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalıen_US
dc.authorid0000-0002-1423-0435en_US
dc.identifier.volume22en_US
dc.identifier.issue18en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.2174/1389557522666220318115350en_US
dc.institutionauthorZurnacı, Fatma Özlem
dc.institutionauthorGüzel, Mustafa
dc.identifier.wosqualityQ2en_US
dc.identifier.wos000860470800005en_US
dc.identifier.scopus2-s2.0-85138400385en_US
dc.identifier.pmid35306995en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster